Calcium Antagonists (Calcium Channel Blockers)

Part of the Contemporary Cardiology book series (CONCARD)


This chapter emphasizes
  • That these excellent blood pressure-lowering agents have been proved in randomized clinical trials (RCTs) to decrease cardiovascular disease (CVD) outcomes in patients with hypertension but carry a significant risk for heart failure (HF) in the elderly and in blacks. This increased incidence of HF appears to be ignored by analysts of RCTs and is discussed in Chapter 8.

  • When to choose a calcium antagonist.

  • Which one to choose.


Calcium Antagonist Left Ventricular Dysfunction Stable Angina Negative Inotropic Effect Coronary Artery Spasm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1977;17:149.PubMedCrossRefGoogle Scholar
  2. 2.
    Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982;307:1618.PubMedCrossRefGoogle Scholar
  3. 3.
    Krikler DM, Harris L, Rowland E. Calcium-channel blockers and beta blockers: Advantages and disadvantages of combination therapy in chronic, stable angina pectoris. Am Heart J 1982;104:702.PubMedCrossRefGoogle Scholar
  4. 4.
    Terry RW. Nifedipine therapy in angina pectoris: Evaluation of safety and side effects. Am Heart J 1982; 104:681.PubMedCrossRefGoogle Scholar
  5. 5.
    Lette J, Gagnon RM, Lemire TG, et al. Rebound of vasospastic angina after cessation of long-term treatment with nifedipine. Can Med Assoc J 1984;130:1169.PubMedGoogle Scholar
  6. 6.
    Choong C YP, Roubin GS, Shen WF, et al. Effects of nifedipine on arterial oxygenation at rest and during exercise in patients with stable angina. J Am Coll Cardiol 1986;8:1461.PubMedCrossRefGoogle Scholar
  7. 7.
    Ballester E, Roca J, Rodriquez-Roisin R, etal. Effectof nifedipine hypoxemia occurring after metacholine challenge in asthma. Thorax 1986;41:468.PubMedGoogle Scholar
  8. 8.
    Diamond JR, Cheung JT, Fang LST. Nifedipine-induced renal dysfunction: Alteration in renal hemodynamics. Am J Med 1984;77:905.PubMedCrossRefGoogle Scholar
  9. 9.
    Bhatnagar SK, Amin MM, Al-Yusuf AR. Diabetogenic effects of nifedipine. BMJ 1984;289:19.PubMedGoogle Scholar
  10. 10.
    McKenney JM, Goodman RP, Wright JT Jr. Use of antihypertensive agents in patients with glucose intolerance. Clin Pharm 1985;4:649.PubMedGoogle Scholar
  11. 11.
    Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994;120:663–664.PubMedGoogle Scholar
  12. 12.
    Khan M Gabriel. Angina. In: Heart Disease, Diagnosis and Therapy. Baltimore, Williams & Wilkins, 1996.Google Scholar
  13. 13.
    Farringer JA, Green JA, O’Rourke, et al. Nifedipine-induced alterations in serumquinidineconcentrations. Am Heart J 1984;108:1570.PubMedCrossRefGoogle Scholar
  14. 14.
    VanLith RM, Appleby DH. Quinidine-nifedipine interaction. Drug Intell Clin Pharm 1985;19:829.Google Scholar
  15. 15.
    Verapamil in acute myocardial infarction: The Danish Study Group on Verapamil in Myocardial Infarction. Eur Heart J 1984;5:516.Google Scholar
  16. 16.
    Scheidt S, Frishman WF, Packer M, et al. Long term effectiveness of verapamil in stable and unstable angina pectoris: One year follow-up of patients treated in placebo-controlled, double-blind randomized clinical trial. Am J Cardiol 1982;50:1185.PubMedCrossRefGoogle Scholar
  17. 17.
    Gulamhusein S, Ko P, Klein GJ. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J 1983;106:145.PubMedCrossRefGoogle Scholar
  18. 18.
    Zalman F, Perloff TK, Durant NN, et al. Acute respiratory failure following intravenous verapamil in Duchenne’s muscular dystrophy. Am Heart J 1983;105:510.PubMedCrossRefGoogle Scholar
  19. 19.
    Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1989;319:385.Google Scholar
  20. 20.
    Goldstein RE, Boccuzzi ST, Cruess D, et al. Diltiazem increases late onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52.PubMedGoogle Scholar
  21. 21.
    Palat GK, Hooker E A, Morahed A. Secondary mania associated with diltiazem. ClinCardiol 1984;7:611.Google Scholar
  22. 22.
    Terwee PM, Rosman JB, Van Der Geest S. Acute renal failure due to diltiazem. Lancet 1984;2:1337.CrossRefGoogle Scholar
  23. 23.
    Lee TH, Friedman PL, Goldman L, et al. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy. Am Heart J 1985;109:163.PubMedCrossRefGoogle Scholar
  24. 24.
    Kuhlmann J. Effects of nifedipine and diltiazem on plasma levels and renal excretions of beta-acetyldigoxin. Clin Pharmacol Ther 1985;37:150.PubMedCrossRefGoogle Scholar
  25. 25.
    Singh S, Doherty J, Udhop V, et al. Amlodipine versus nadolol in patients with stable angina pectoris. Am Heart J 1989;118:1137.PubMedCrossRefGoogle Scholar
  26. 26.
    Lorimer AR, Smedsrud T, Walker P, Tyler HM. Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1988;12(Suppl 7):S89.PubMedCrossRefGoogle Scholar
  27. 27.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755.PubMedCrossRefGoogle Scholar
  28. 28.
    Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm: A controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983;308:619.PubMedCrossRefGoogle Scholar
  29. 29.
    PRAISE: Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: For the Prospective Randomised Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107.PubMedCrossRefGoogle Scholar
  30. 30.
    Staessen JA, Fagard R, Lutgarde T, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: For the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757.PubMedCrossRefGoogle Scholar
  31. 31.
    Michels KB, Rosner B A, Manson JE, et al. Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: The Nurses’ Health Study. Circulation 1998;97:1540.PubMedGoogle Scholar
  32. 32.
    Califf RM, Kramer JM. What have we learned from the calcium channel blocker controversy? Circulation 1998;97:1529.PubMedGoogle Scholar
  33. 33.
    Cutler JA. Calcium-channel blockers for hypertension: Uncertainty continues. N Engl J Med 1998;338: 679.PubMedCrossRefGoogle Scholar
  34. 34.
    Borhani NO, Mercury M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomised controlled trial. JAMA 1996;276:785.PubMedCrossRefGoogle Scholar
  35. 35.
    Estacio RO, Jeffers B W, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338:645.PubMedCrossRefGoogle Scholar
  36. 36.
    Tatti P, Pahor M, Byington RP, et al. Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). Circulation 1997;96(Suppl I):1–764.Google Scholar
  37. 37.
    Pahor M, Kritchevsky SB, Zuccla G, et al. Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998;21:193.PubMedGoogle Scholar
  38. 38.
    Matterson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six hypertensive agents with placebo. N Engl J Med 1993;328:914.CrossRefGoogle Scholar
  39. 39.
    Khan M Gabriel. Valvular heart disease. In: Heart Disease, Diagnosis and Therapy. Baltimore, Williams & Wilkins, 1996.Google Scholar
  40. 40.
    Subramanian B, Bowles MJ, Davies AB, Raftery EB. Combined therapy with verapamil and propranolol in chronic stable angina. Am J Cardiol 1982;49:125.PubMedCrossRefGoogle Scholar
  41. 41.
    Subramanian VB. Calcium Antagonists in Chronic Stable Angina Pectoris. Amsterdam, Excerpta Medica/ Elsevier, 1983, p 213.Google Scholar
  42. 42.
    Theroux P, Taeymans Y, Waters DD. Calcium antagonists: Clinical use in the treatment of angina. Drugs 1983;25:178.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations